evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

122 questions · 122 findings · 14 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 22 · 18%GRADE not reported 5 · 4.1%Very low 18 · 14.8%Low 37 · 30.3%Moderate 34 · 27.9%High 6 · 4.9%

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Asparaginase‐associated toxicity · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher asparaginase‐associated toxicity compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Overall survival · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in overall survival compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Event‐free survival · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in event‐free survival compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Monthly pegloticase vs placebo

Serum urate normalisation ‐ not reported · participants with tophi in gout

The review found no eligible studies for this question.

1 finding from 1 review

Monthly pegloticase vs placebo

Withdrawals due to adverse events · participants with tophi in gout

Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Monthly pegloticase vs placebo

Total adverse events · participants with tophi in gout

Monthly pegloticase showed no clear difference in total adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Monthly pegloticase vs placebo

Proportion with complete resolution of a target tophus · participants with tophi in gout

Monthly pegloticase showed no clear difference in proportion with complete resolution of tophi compared with placebo (moderate certainty).

1 finding from 1 review

Monthly pegloticase vs placebo

Joint pain reduction ‐ not reported · participants with tophi in gout

The review found no eligible studies for this question.

1 finding from 1 review

Pegloticase every two weeks (biweekly) vs placebo

Proportion with complete resolution of a target tophus · participants with tophi in gout

Pegloticase every two weeks (biweekly) probably leads to higher proportion with complete resolution of tophi compared with placebo (moderate certainty).

1 finding from 1 review